{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:33:17Z","timestamp":1788791597684,"version":"build-2803163510"},"reference-count":58,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015374","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T14:53:17Z","timestamp":1639061597000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chemotherapy for second-stage human African trypanosomiasis: drugs in use"],"prefix":"10.1002","volume":"2021","author":[{"given":"Vittoria","family":"Lutje","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences; Liverpool School of Tropical Medicine; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Probyn","sequence":"additional","affiliation":[{"name":"Cochrane Response; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Seixas","sequence":"additional","affiliation":[{"name":"Institute of Hygiene and Tropical Medicine and Global Health and Tropical Medicine R&D Center; NOVA University; Lisbon Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Bergman","sequence":"additional","affiliation":[{"name":"Cochrane Response; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Villanueva","sequence":"additional","affiliation":[{"name":"Cochrane Response; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"key":"10.1002\/14651858.CD015374-BIB0001|cit1","unstructured":"Follow-up abbreviated clinical study report DNDiFEX004 - fexinidazole. Efficacy and safety of fexinidazole compared to nifurtimox-eflornithine combination therapy (NECT) in patients with late-stage human African trypanosomiasis (HAT) due to T. b. gambiense: a pivotal, non-inferiority, randomised, open-label, multicentre study Data on file"},{"key":"10.1002\/14651858.CD015374-BIB0002|cit2","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use Assessment report fexinidazole winthrop; 2018 www.ema.europa.eu\/en\/documents\/medicine-outside-eu\/fexinidazole-winthrop-assessment-report_en-0.pdf\u00a0"},{"issue":"10116","key":"10.1002\/14651858.CD015374-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","article-title":"Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial","volume":"391","author":"Mesu","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD015374-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/cid\/cis886","article-title":"Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Medecins Sans Frontieres experience in the Democratic Republic of the Congo","volume":"56","author":"Alirol","year":"2013","journal-title":"Clinical Infectious Diseases"},{"issue":"10116","key":"10.1002\/14651858.CD015374-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0140-6736(18)30019-9","article-title":"Oral fexinidazole for human African trypanosomiasis","volume":"391","author":"Chappuis","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD015374-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1128\/AAC.04101-14","article-title":"Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness","volume":"59","author":"Jansson-L\u00f6fmark","year":"2015","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD015374-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13071-018-2634-x","article-title":"A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda","volume":"11","author":"Kansiime","year":"2018","journal-title":"Parasites & Vectors"},{"issue":"6","key":"10.1002\/14651858.CD015374-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"e0006504","DOI":"10.1371\/journal.pntd.0006504","article-title":"Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: a critical appraisal of 23 years of experience in the Democratic Republic of Congo","volume":"12","author":"Kazumba","year":"2018","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015374-BIB0009|cit9","first-page":"59","article-title":"NECT feld phase IIIb trial: final effectiveness in adults and children results","volume":"18","author":"Mord","year":"2013","journal-title":"Tropical Medicine & International Health"},{"key":"10.1002\/14651858.CD015374-BIB0010|cit10","unstructured":"Human African trypanosomiasis: first in man clinical trial of a new medicinal product, the fexinidazole clinicaltrials.gov\/ct2\/show\/NCT00982904"},{"key":"10.1002\/14651858.CD015374-BIB0011|cit11","unstructured":"Fexinidazole (1200mg) bioavailability under different food intake conditions clinicaltrials.gov\/ct2\/show\/NCT01340157"},{"key":"10.1002\/14651858.CD015374-BIB0012|cit12","unstructured":"Multiple dose study to evaluate security, tolerance and pharmacokinetic of fexinidazole (drug candidate for human African trypanosomiasis) administered with a loading dose and with food clinicaltrials.gov\/ct2\/show\/NCT01483170"},{"key":"10.1002\/14651858.CD015374-BIB0013|cit13","unstructured":"Bioequivalence study - reference clinical fexinidazole tablet versus proposed market formulation clinicaltrials.gov\/ct2\/show\/NCT02571062"},{"issue":"6","key":"10.1002\/14651858.CD015374-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"e0007381","DOI":"10.1371\/journal.pntd.0007381","article-title":"The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis","volume":"13","author":"Pelfrene","year":"2019","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"3","key":"10.1002\/14651858.CD015374-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pt.2017.12.002","article-title":"Fexinidazole: a new drug for African sleeping sickness on the horizon","volume":"34","author":"Pollastri","year":"2018","journal-title":"Trends in Parasitology"},{"issue":"11","key":"10.1002\/14651858.CD015374-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"e1920","DOI":"10.1371\/journal.pntd.0001920","article-title":"In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness","volume":"6","author":"Schmid","year":"2012","journal-title":"PLOS Neglected Tropical Diseases"},{"key":"10.1002\/14651858.CD015374-BIB0017|cit17","unstructured":"Tarral A Valverde O Blesson S Strub-Wourgaft N Hosvepian L Evene E Single-dose safety, pharmacokinetics (PK) and pharmacodynamics (PD) of fexinidazole in healthy subjects. 7th European Congress on Tropical Medicine & International Health. 2011 www.dndi.org\/media-centre\/events\/events-2011\/216-media-centre\/events\/980-barcelona.html(DW note: authors please check link as it's no longer valid. Do you mean https:\/\/dndi.org\/wp-content\/uploads\/2011\/10\/Fexi%20Antoine%20FINAL.pdf?)"},{"issue":"6","key":"10.1002\/14651858.CD015374-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40262-014-0136-3","article-title":"Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies","volume":"53","author":"Tarral","year":"2014","journal-title":"Clinical Pharmacokinetics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015374-BIB0019|cit19","first-page":"325","article-title":"Nifurtimox eflornithine combination therapy phase IIIb field trial (NECT Field): final effectiveness and safety results","volume":"20","author":"Valverde Mordt","year":"2015","journal-title":"Tropical Medicine & International Health"},{"issue":"4","key":"10.1002\/14651858.CD015374-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"e02515","DOI":"10.1128\/AAC.02515-18","article-title":"Pharmacokinetic-pharmacodynamic assessment of the hepatic and bone marrow toxicities of the new trypanoside fexinidazole","volume":"63","author":"Watson","year":"2019","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD015374-BIB0021|cit21","unstructured":"Prospective study on efficacy and safety of acoziborole (SCYX-7158) in patients infected by human African trypanosomiasis due to T. b. gambiense (OXA002) clinicaltrials.gov\/ct2\/show\/NCT03087955"},{"issue":"7168","key":"10.1002\/14651858.CD015374-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","article-title":"Confidence intervals for the number needed to treat","volume":"317","author":"Altman","year":"1998","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD015374-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"e0006925","DOI":"10.1371\/journal.pntd.0006925","article-title":"The elimination of human African trypanosomiasis is in sight: report from the third WHO stakeholders meeting on elimination of gambiense human African trypanosomiasis","volume":"12","author":"Barrett","year":"2018","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"9709","key":"10.1002\/14651858.CD015374-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","article-title":"Human African trypanosomiasis","volume":"375","author":"Brun","year":"2010","journal-title":"Lancet"},{"issue":"10110","key":"10.1002\/14651858.CD015374-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/S0140-6736(17)31510-6","article-title":"Human African trypanosomiasis","volume":"390","author":"B\u00fcscher","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015374-BIB0026|cit26","unstructured":"Covidence Veritas Health Innovation"},{"issue":"11","key":"10.1002\/14651858.CD015374-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1586\/14787210.2014.959496","article-title":"Treatment options for second-stage gambiense human African trypanosomiasis","volume":"12","author":"Eperon","year":"2014","journal-title":"Expert Review of Anti-infective Therapy"},{"key":"10.1002\/14651858.CD015374-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/RRTM.S34399","article-title":"Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis","volume":"3","author":"Franco","year":"2012","journal-title":"Research and Reports in Tropical Medicine"},{"issue":"6","key":"10.1002\/14651858.CD015374-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1017\/S0031182013002102","article-title":"The journey towards elimination of gambiense human African trypanosomiasis: not far, nor easy","volume":"141","author":"Franco","year":"2014","journal-title":"Parasitology"},{"issue":"5","key":"10.1002\/14651858.CD015374-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"e0005585","DOI":"10.1371\/journal.pntd.0005585","article-title":"Monitoring the elimination of human African trypanosomiasis: update to 2014","volume":"11","author":"Franco","year":"2017","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"12","key":"10.1002\/14651858.CD015374-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"e0006890","DOI":"10.1371\/journal.pntd.0006890","article-title":"Monitoring the elimination of human African trypanosomiasis: update to 2016","volume":"12","author":"Franco","year":"2018","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"5","key":"10.1002\/14651858.CD015374-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"e0008261","DOI":"10.1371\/journal.pntd.0008261","article-title":"Monitoring the elimination of human African trypanosomiasis at continental and country level: update to 2018","volume":"14","author":"Franco","year":"2020","journal-title":"PLOS Neglected Tropical Diseases"},{"key":"10.1002\/14651858.CD015374-BIB0033|cit33","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"4","key":"10.1002\/14651858.CD015374-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"20","key":"10.1002\/14651858.CD015374-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD015374-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency is preferable to testing for heterogeneity in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015374-BIB0037|cit37","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015374-BIB0038|cit38","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"issue":"12","key":"10.1002\/14651858.CD015374-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"e0004299","DOI":"10.1371\/journal.pntd.0004299","article-title":"Genomic and proteomic studies on the mode of action of oxaboroles against the African trypanosome","volume":"9","author":"Jones","year":"2015","journal-title":"PLOS Neglected Tropical Diseases"},{"key":"10.1002\/14651858.CD015374-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fimmu.2019.00039","article-title":"Clinical and neuropathogenetic aspects of human African trypanosomiasis","volume":"10","author":"Kennedy","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1002\/14651858.CD015374-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-3156.2005.01403.x","article-title":"Review Article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up","volume":"10","author":"Lejon","year":"2005","journal-title":"Tropical Medicine & International Health"},{"issue":"2","key":"10.1002\/14651858.CD015374-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S1473-3099(19)30612-7","article-title":"New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice","volume":"20","author":"Lindner","year":"2020","journal-title":"Lancet Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD015374-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"e999","DOI":"10.1016\/S2214-109X(21)00208-4","article-title":"Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study","volume":"9","author":"Mesu","year":"2021","journal-title":"Lancet Global Health"},{"key":"10.1002\/14651858.CD015374-BIB0044|cit44","unstructured":"Human African trypanosomiasis: first in man clinical trial of a new medicinal product, the SCYX-7158 clinicaltrials.gov\/ct2\/show\/NCT01533961"},{"key":"10.1002\/14651858.CD015374-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0065-308X(01)49038-5","article-title":"The epidemiology and control of human African trypanosomiasis","volume":"49","author":"P\u00e9pin","year":"2001","journal-title":"Advances in Parasitology"},{"issue":"9683","key":"10.1002\/14651858.CD015374-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015374-BIB0047|cit47","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD015374-BIB0048|cit48","first-page":"65","volume-title":"The African trypanosomes. Series: World Class Parasites, Vol. 1","author":"Seed","year":"2001"},{"issue":"7357","key":"10.1002\/14651858.CD015374-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/bmj.325.7357.203","article-title":"Human African trypanosomiasis","volume":"325","author":"Stich","year":"2002","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD015374-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness","volume":"4","author":"Torreele","year":"2010","journal-title":"PLOS Neglected Tropical Diseases"},{"key":"10.1002\/14651858.CD015374-BIB0051|cit51","unstructured":"World Health Organization Recommendations of the informal consultation on issue for clinical product development for human African trypanosomiasis; Geneva, Switzerland. 9-10 September 2004 Available at www.who.int\/neglected_diseases\/mediacentre\/Final%20Clinical_products_for_trypanosomiasis%20November%2007.pdf"},{"key":"10.1002\/14651858.CD015374-BIB0052|cit52","unstructured":"World Health Organization WHO model list of essential medicines, 16th list (updated); March 2010 Available at www.who.int\/medicines\/publications\/essentialmedicines\/Updated_sixteenth_adult_list_en.pdf"},{"key":"10.1002\/14651858.CD015374-BIB0053|cit53","unstructured":"World Health Organization Accelerating work to overcome neglected tropical diseases: a roadmap for implementation; 2012 Available at www.who.int\/neglected_diseases\/NTD_RoadMap_2012_Fullversion.pdf"},{"key":"10.1002\/14651858.CD015374-BIB0054|cit54","unstructured":"World Health Organization Report of a WHO meeting on elimination of African trypanosomiasis (Trypanosoma brucei gambiense); 2013 who.int\/publications\/i\/item\/WHO-HTM-NTD-IDM-2013.4"},{"key":"10.1002\/14651858.CD015374-BIB0055|cit55","unstructured":"World Health Organization WHO interim guidelines for the treatment of gambiense human African trypanosomiasis; 2019 apps.who.int\/iris\/bitstream\/handle\/10665\/326178\/9789241550567-eng.pdf?ua=1"},{"issue":"4","key":"10.1002\/14651858.CD015374-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006201","article-title":"Chemotherapy of second-stage Human African trypanosomiasis","author":"Lutje","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD015374-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006201.pub2","article-title":"Chemotherapy for second stage Human African trypanosomiasis","author":"Lutje","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD015374-BIB0058|cit58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006201.pub3","article-title":"Chemotherapy for second-stage human African trypanosomiasis","author":"Lutje","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T10:09:15Z","timestamp":1692698955000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015374"}},"subtitle":[],"editor":[{"name":"Cochrane Infectious Diseases Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,9]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015374","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,9]]}}}